Gene therapy developer PsiOxus Therapeutics on Thursday announced it has appointed Tom Lillie as its chief medical officer. Lillie previously held senior oncology roles at Amgen (NASDAQ: [[ticker:AMGN]]) and MSD (NYSE: [[ticker:MRK]]) (as Merck is known outside of the US and Canada). The Oxford, England-based company also said it moved its third gene therapy for cancer patients into the clinic.
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
View all posts by Sarah de Crescenzo
